A decision is expected in the fourth quarter of 2025.

CCMC Health System announces the results of a four-years long study on the efficacy of a novel treatment intervention, the ...

Itching, or pruritus, is a common symptom in people with advanced chronic kidney disease (CKD ... In 2021, the Food and Drug Administration (FDA) approved a drug to treat moderate to severe ...

Learn how the FIDELITY risk model helps clinicians predict hyperkalaemia in CKD and diabetes-read on for clinical insights.

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

Compare Dialysis Centers examined Centers for Disease Control and Prevention data and other sources to explore the risk factors for chronic kidney disease, or CKD, and its growing ubiquity among ...

The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...